Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)
Status:
Completed
Trial end date:
2020-02-28
Target enrollment:
Participant gender:
Summary
The objective of this post-marketing surveillance study is to evaluate the incidence of
adverse events in Japanese subjects with pulmonary arterial hypertension treated with
ambrisentan basd on prescribing information under the conditions of general clinical practice
and also to grasp the following items;
1. Unknown adverse drug reactions (ADRs)
2. Incidence of ADRs to medical products in actual clinical practice
3. Factors influencing safety of ambrisentan
4. Factors influencing efficacy of ambrisentan
5. Prognosis of subjects as well as efficacy and safety of ambrisentan in long-term use
(VOLIBRIS® is a trademark of Gilead Sciences, Inc,. that GSK uses under license.)